MedTrace Logo

Postmarketing Surveillance Study With MOBEC®

NCT02182726 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4760

Last updated 2014-07-09

No results posted yet for this study

Summary

The aim of the study is to investigate

* the indication for MOBEC in a dose of 15 mg per day
* the treatments patients were receiving before switching to 15 mg MOBEC
* how treatment with 15 mg is assessed compared with previous treatment
* how effective and safe treatment with 15 mg MOBEC is considered

Conditions

Interventions

DRUG

MOBEC

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2001-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02182726 on ClinicalTrials.gov